Product literacy
Tirzepatide Beyond-Use Dates
A beyond-use date is assigned by a compounding pharmacy based on its own stability assessment for that preparation. It is not the same as a manufacturer expiry date, which derives from extensive stability testing, and it is frequently much shorter. Multi-month compounded supplies raise the question of whether later vials remain within their dating.
Key takeaways
- A beyond-use date is assigned by the compounding pharmacy, not derived from manufacturer stability testing.
- Beyond-use dates are frequently much shorter than manufacturer expiry dates.
- Multi-month supplies can include vials that reach their beyond-use date before use.
- Storage conditions affect whether a beyond-use date remains meaningful.
- Ask for the beyond-use date policy before committing to a multi-month plan.
| Who assigns it | The compounding pharmacy |
|---|---|
| Basis | The pharmacy's stability assessment for that preparation |
| Compared with manufacturer expiry | Typically much shorter |
| Risk with multi-month supplies | Later vials may reach dating before use |
| Effect of storage failures | Can invalidate the assigned dating |
| What to ask | The beyond-use date policy and the dating on each vial supplied |
Why is a beyond-use date shorter than an expiry date?
Because it rests on far less data. A manufacturer's expiry date follows extensive stability testing of a specific formulation in specific packaging under defined conditions. A compounding pharmacy assigns a beyond-use date using applicable standards and its own assessment, without that testing programme behind it.
The shorter dating is appropriate caution rather than a defect. It does mean the date carries real constraints on how long a supply remains usable.
How does this interact with multi-month purchasing?
Directly, and it is a question people rarely ask before prepaying. If a provider ships three or six months of supply at once and the beyond-use dating is shorter than that period, the last vials may exceed their dating before you reach them. That converts a discount into a partial write-off.
Ask specifically: what is the beyond-use date on each vial in a multi-month shipment, and what happens if a vial reaches it before use.
Does a temperature excursion change the beyond-use date?
It can invalidate the assumptions the dating was based on. A beyond-use date assumes storage under specified conditions; a shipment that arrived warm may no longer meet them, regardless of what the printed date says. That is a question for the pharmacy — see warm shipment.
What the evidence shows
- That beyond-use dates are pharmacy-assigned and typically shorter than manufacturer expiry dates.
- That storage conditions affect whether the dating remains meaningful.
What the evidence does not show
- Whether a specific vial remains usable — that requires the dispensing pharmacy's assessment.
- A general beyond-use period applicable to all compounded tirzepatide.
Related: Storage · Warm shipment
What exactly differs between approved and compounded tirzepatide?
| Attribute | FDA-approved (Zepbound / Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Premarket FDA review | Yes — safety, efficacy, and quality reviewed | No |
| Randomised trial evidence | SURMOUNT and SURPASS programmes | None identified |
| Concentration | Fixed and verified by the manufacturer | Varies by pharmacy; not independently verified |
| Presentation | Fixed-dose pen or autoinjector | Commonly a vial requiring measurement |
| Dating | Manufacturer expiry from stability testing | Pharmacy-assigned beyond-use date |
| Adverse-event capture | Systematic post-marketing surveillance | Less systematic |
| Consumer verification route | FDA approval record | State board licence lookup |
| Group | FDA-approved | Compounded |
|---|---|---|
| Randomised trials | 6 | 0 |
| Verified concentration | 1 | 0 |
| Premarket review | 1 | 0 |
What does the regulatory framework actually say?
Compounding occupies a specific legal position that is frequently described inaccurately in marketing. A 503A pharmacy prepares patient-specific preparations against individual prescriptions and is licensed by a state board of pharmacy. A 503B outsourcing facility may prepare larger batches without individual prescriptions, registers with the FDA, and is subject to current good manufacturing practice requirements. Neither route produces an FDA-approved product.
That last sentence is the one most often blurred. Registration is not approval. Inspection is not approval. Operating legally is not approval. Approval is a specific determination that the FDA has reviewed evidence of safety, effectiveness, and manufacturing quality for a particular product before it is marketed, and no compounded preparation has been through that process.
| Term | What it actually means | What it does not mean |
|---|---|---|
| FDA approved | The agency reviewed safety, efficacy and quality evidence before marketing | Applies to any compounded preparation |
| FDA registered | The facility filed a registration with the agency | The product was reviewed or approved |
| FDA inspected | The agency conducted a facility inspection | The product was approved, or that the inspection found no problems |
| State licensed | A state board authorised the pharmacy to operate | Any federal review of the product |
| cGMP compliant | The facility follows manufacturing practice standards | The specific product was evaluated for safety or efficacy |
| Third-party tested | A laboratory analysed a sample | Systematic batch verification, unless the scope and frequency are disclosed |
What can a patient actually verify before paying?
Where randomised evidence is absent, verification of the supply chain takes its place as the meaningful check. The useful feature of these checks is that they are all things a reader can do independently, against public records, before any money changes hands.
| Check | How to do it | What a refusal or gap tells you |
|---|---|---|
| Pharmacy legal name | Ask the provider in writing before enrolling | A provider unwilling to name its pharmacy is withholding the single most useful fact |
| State licence | Search the licensing state board's public register | An unlisted or lapsed licence is disqualifying |
| 503A or 503B status | Ask, then check the FDA outsourcing facility register for 503B claims | A 503B claim absent from the register is a serious discrepancy |
| Disciplinary history | State board records and enforcement notices | Prior action is not automatically disqualifying but is material |
| Concentration in mg/mL | Ask before ordering; confirm on the dispensing label | An unwillingness to state concentration makes safe use impossible |
| Beyond-use date policy | Ask what date is assigned and on what basis | No stated policy suggests weak quality systems |
| Cold-chain and excursion policy | Ask who bears risk if a shipment arrives warm | No policy means the risk sits with you |
A provider that answers all seven readily has demonstrated something meaningful. One that treats these as intrusive has also answered, in a different way. This is not a guarantee of quality — it is the strongest signal available to a consumer in a market where the usual guarantee, regulatory approval, does not exist.
What are the limits of what this page can tell you?
This page describes a regulatory framework and a verification method. Both have limits that matter.
- Regulatory status changes, and enforcement priorities change with it. Statements here carry the verification date shown above.
- State licensing requirements differ, so a check that is straightforward in one state may be harder in another.
- Verification of a pharmacy's licence establishes that it is authorised to operate. It does not establish the quality of any particular preparation.
- No verification step available to a consumer substitutes for the premarket review that approved products undergo.
What does this page cover, and what does it deliberately leave out?
This page addresses BUD versus expiration and storage and multi-month supplies, organised around the primary question of tirzepatide beyond use date. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Bud versus expiration | Covered on this page | Regulatory or policy source |
| Storage and multi-month supplies | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the dispensing pharmacy and your prescriber |
What are the limits of what this page can tell you?
Every page on this site rests on a specific regulatory position on compounded preparations, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the dispensing pharmacy and your prescriber.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on tirzepatide beyond use date.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 5 technical terms this page uses, including 503A, 503B, beyond-use date, compounded — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| beyond-use date | The date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| mg/mL | Milligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations. |
Frequently asked questions
What is a beyond-use date?
A date assigned by the compounding pharmacy based on its own stability assessment for that preparation.
Is it the same as an expiry date?
No. Manufacturer expiry dates derive from extensive stability testing; beyond-use dates are typically much shorter.
What if I buy six months at once?
Ask whether the beyond-use dating covers that period — later vials may otherwise exceed it before use.
Does a warm shipment affect it?
It can invalidate the assumptions behind the dating. Ask the pharmacy.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.